Literature DB >> 15565653

A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women.

M Macé1, L Sissoeff, A Rudent, L Grangeot-Keros.   

Abstract

OBJECTIVES: Serological diagnosis of CMV primary infection is usually based on the detection of specific IgM antibody. However, as the presence of IgM antibody is not always correlated with primary infection, measurement of IgG avidity must be performed. The aim of our study was to evaluate the best procedure for serological diagnosis of CMV primary infection. In other words, is it better to first search for IgM antibody, and, if positive, then measure IgG avidity, or first measure IgG avidity without the detection of IgM antibody? MATERIALS: CMV-IgM detection and CMV-IgG avidity measurement were performed on 310 IgG positive sera from pregnant women.
RESULTS: CMV-IgM antibody was detected positive for 9 of 310 sera. Using CMV-IgG avidity index (AI), dating of infection was difficult in 81/310 cases (26%), while it failed in only 3/310 cases using CMV-IgM plus CMV-IgG AI.
CONCLUSION: The diagnosis of primary CMV infection can be based on the detection of CMV-IgM antibody first and then on the measurement of CMV-IgG AI. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565653     DOI: 10.1002/pd.1001

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  10 in total

1.  HIV, Cytomegalovirus, and Malaria Infections during Pregnancy Lead to Inflammation and Shifts in Memory B Cell Subsets in Kenyan Neonates.

Authors:  Kee Thai Yeo; Paula Embury; Timothy Anderson; Peter Mungai; Indu Malhotra; Christopher King; James Kazura; Arlene Dent
Journal:  J Immunol       Date:  2019-01-23       Impact factor: 5.422

2.  Potential impact of different cytomegalovirus (CMV) IgM assays on an algorithm requiring IgM reactivity as a criterion for measuring CMV IgG avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Andrew Brenner; Nancy Pitstick; Marc Roger Couturier
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

3.  Performance of a cytomegalovirus IgG enzyme immunoassay kit modified to measure avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Susan M Novak-Weekley
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

4.  Cytomegalovirus infection in pregnancy: review of the literature.

Authors:  Silvia Bonalumi; Angelica Trapanese; Angelo Santamaria; Laura D'Emidio; Luisa Mobili
Journal:  J Prenat Med       Date:  2011-01

5.  Overview of the diagnosis of cytomegalovirus infection.

Authors:  S A Ross; Z Novak; S Pati; S B Boppana
Journal:  Infect Disord Drug Targets       Date:  2011-10

6.  Cytomegalovirus seroprevalence, recurrence, and antibody levels: Associations with cadmium and lead exposures in the general United States population.

Authors:  Catherine M Bulka; Paige A Bommarito; Allison E Aiello; Rebecca C Fry
Journal:  Environ Epidemiol       Date:  2020-06-05

7.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

Review 8.  Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

Review 9.  Clinical Significance of IgG Avidity Testing and Other Considerations in the Diagnosis of Congenital Cytomegalovirus Infection: A Review Update.

Authors:  Idris Abdullahi Nasir; Adamu Babayo; Muhammad Sagir Shehu
Journal:  Med Sci (Basel)       Date:  2016-03-08

10.  Seropositivity of cytomegalovirus in patients with recurrent pregnancy loss.

Authors:  Roya Sherkat; Mohsen Meidani; Hossein Zarabian; Abbas Rezaei; Ali Gholamrezaei
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.